Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-carbohydrate diet versus orlistat for nonalcoholic fatty liver disease
ChiCTR1900027172Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of orlistat in metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: hepatic fat fraction at week 24, liver pathology at week 24 and 3 more. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
orlistat
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR1900027172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027172.